Plato Investment Management Ltd Invests $1.34 Million in IQVIA Holdings Inc. $IQV

Plato Investment Management Ltd acquired a new stake in IQVIA Holdings Inc. (NYSE:IQV) in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 6,960 shares of the medical research company’s stock, valued at approximately $1,337,000.

Several other hedge funds have also recently bought and sold shares of the business. Financial Freedom LLC bought a new stake in shares of IQVIA during the 1st quarter worth about $25,000. Ascentis Independent Advisors acquired a new stake in IQVIA in the 1st quarter worth approximately $25,000. International Assets Investment Management LLC bought a new stake in IQVIA during the fourth quarter worth approximately $27,000. Gilpin Wealth Management LLC bought a new position in shares of IQVIA in the fourth quarter valued at approximately $27,000. Finally, CrossGen Wealth LLC acquired a new stake in shares of IQVIA in the fourth quarter worth $28,000. 89.62% of the stock is owned by institutional investors and hedge funds.

IQVIA Trading Up 1.9%

Shares of IQV opened at $241.09 on Tuesday. IQVIA Holdings Inc. has a 12-month low of $154.50 and a 12-month high of $251.36. The company has a quick ratio of 0.71, a current ratio of 0.71 and a debt-to-equity ratio of 2.18. The firm has a market capitalization of $39.68 billion, a price-to-earnings ratio of 29.91, a P/E/G ratio of 2.01 and a beta of 1.18. The stock’s 50-day moving average price is $207.80 and its 200 day moving average price is $186.72.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Tuesday, July 28th. The medical research company reported $3.15 EPS for the quarter, topping analysts’ consensus estimates of $3.03 by $0.12. The company had revenue of $4.37 billion during the quarter, compared to the consensus estimate of $4.30 billion. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The company’s quarterly revenue was up 8.7% on a year-over-year basis. During the same quarter last year, the company earned $2.81 EPS. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. As a group, research analysts predict that IQVIA Holdings Inc. will post 11.57 earnings per share for the current year.

IQVIA declared that its board has approved a stock buyback program on Thursday, May 7th that authorizes the company to buyback $2.00 billion in shares. This buyback authorization authorizes the medical research company to reacquire up to 6.8% of its stock through open market purchases. Stock buyback programs are generally a sign that the company’s board of directors believes its shares are undervalued.

Analyst Upgrades and Downgrades

Several brokerages recently commented on IQV. Wall Street Zen upgraded shares of IQVIA from a “hold” rating to a “buy” rating in a report on Saturday, August 1st. Robert W. Baird raised their price target on IQVIA from $252.00 to $287.00 and gave the company an “outperform” rating in a research report on Wednesday, July 29th. TD Cowen boosted their price objective on IQVIA from $233.00 to $288.00 and gave the stock a “buy” rating in a research report on Wednesday, July 29th. Royal Bank Of Canada increased their target price on IQVIA from $221.00 to $247.00 and gave the company an “outperform” rating in a research note on Wednesday, July 29th. Finally, Morgan Stanley reaffirmed an “equal weight” rating and issued a $200.00 price target (down from $225.00) on shares of IQVIA in a research report on Wednesday, June 17th. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, IQVIA has a consensus rating of “Moderate Buy” and an average target price of $241.88.

Insider Buying and Selling at IQVIA

In other news, insider Bhavik Patel sold 1,855 shares of the stock in a transaction on Friday, July 31st. The shares were sold at an average price of $235.27, for a total value of $436,425.85. Following the completion of the transaction, the insider owned 1,348 shares in the company, valued at approximately $317,143.96. This represents a 57.91% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Eric Sherbet sold 5,000 shares of the firm’s stock in a transaction dated Wednesday, July 29th. The stock was sold at an average price of $249.16, for a total transaction of $1,245,800.00. Following the transaction, the insider directly owned 20,999 shares of the company’s stock, valued at $5,232,110.84. The trade was a 19.23% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 12,913 shares of company stock worth $3,098,793. Corporate insiders own 1.70% of the company’s stock.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.